CI
VRTX icon

Capital International’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital International’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.3M Buy
97,334
+1,460
+2% +$647K 1.58% 15
2026
Q1 		$42.8M Buy
95,874
+262
+0.3% +$122K 1.59% 14
2025
Q4 		$43.3M Sell
95,612
-25,675
-21% -$11.1M 1.53% 12
2025
Q3 		$47.5M Sell
121,287
-6,320
-5% -$2.64M 1.72% 13
2025
Q2 		$56.8M Buy
127,607
+15,061
+13% +$6.94M 2.18% 7
2025
Q1 		$54.6M Buy
112,546
+1,975
+2% +$920K 2.38% 8
2024
Q4 		$44.5M Buy
110,571
+10,966
+11% +$5.08M 1.82% 9
2024
Q3 		$46.3M Sell
99,605
-866
-0.9% -$416K 2% 8
2024
Q2 		$47.1M Buy
100,471
+915
+0.9% +$397K 2.17% 7
2024
Q1 		$41.6M Buy
99,556
+14,680
+17% +$6.21M 1.99% 8
2023
Q4 		$34.5M Buy
84,876
+3,377
+4% +$1.25M 1.77% 7
2023
Q3 		$28.3M Buy
81,499
+1,259
+2% +$440K 1.63% 10
2023
Q2 		$28.2M Buy
80,240
+10,527
+15% +$3.55M 1.58% 8
2023
Q1 		$22M Buy
69,713
+4,258
+7% +$1.28M 1.32% 14
2022
Q4 		$18.9M Sell
65,455
-5,395
-8% -$1.64M 1.3% 17
2022
Q3 		$20.5M Buy
70,850
+7,483
+12% +$2.15M 1.43% 12
2022
Q2 		$17.9M Buy
63,367
+111
+0.2% +$29.7K 1.34% 13
2022
Q1 		$16.5M Sell
63,256
-20,335
-24% -$4.83M 0.94% 26
2021
Q4 		$18.4M Buy
83,591
+10,036
+14% +$1.95M 0.93% 24
2021
Q3 		$13.3M Sell
73,555
-12,473
-14% -$2.44M 0.73% 38
2021
Q2 		$17.3M Buy
86,028
+6,144
+8% +$1.29M 0.96% 25
2021
Q1 		$17.2M Sell
79,884
-1,275
-2% -$280K 1.04% 21
2020
Q4 		$19.2M Sell
81,159
-1,091
-1% -$250K 1.12% 21
2020
Q3 		$22.4M Buy
82,250
+16,221
+25% +$4.48M 1.52% 14
2020
Q2 		$19.2M Buy
66,029
+3,004
+5% +$814K 1.79% 13
2020
Q1 		$15M Buy
+63,025
New +$14.5M 1.68% 13
2018
Q3 		– Sell
-6,831
Closed -$1.16M – 167
2018
Q2 		$1.16M Buy
6,831
+797
+13% +$124K 0.2% 117
2018
Q1 		$983K Buy
+6,034
New +$986K 0.18% 126

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital International's VRTX Position: Q2 2026 in Review

Capital International increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q2 2026, buying an estimated $647K and bringing the position to 97,334 shares worth $48.3M. The position accounts for 1.58% of the portfolio, ranked #15.

Capital International first reported a position in VRTX in Q1 2018 and has held it in 28 quarters since. The position peaked at $56.8M in Q2 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Capital International held 97,334 shares of Vertex Pharmaceuticals worth $48.3M as of Q2 2026.
  • Capital International bought 1,460 Vertex Pharmaceuticals shares in Q2 2026, an estimated $647K.
  • Vertex Pharmaceuticals made up 1.58% of Capital International's portfolio in Q2 2026, its #15 holding.
  • Capital International first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 28 quarters since.
  • Capital International's Vertex Pharmaceuticals position peaked at $56.8M in Q2 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital International's 13F filing for Q2 2026, filed 12 Aug 2026.